Ney Carter Borges: Circadian Disruption and Melatonin Deficiency as Cardiovascular Risk Factors
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn about a recent article by Jarosław Nuszkiewicz et al, adding:
“Circadian Rhythm Disruption and Cardiovascular Risk: The Role of Melatonin
Circadian rhythms are endogenous 24-hour cycles that regulate key cardiovascular functions, including blood pressure, heart rate, vascular tone, and metabolic homeostasis.
These rhythms are orchestrated by the suprachiasmatic nucleus (SCN), which synchronizes peripheral clocks through neuroendocrine signaling, particularly via melatonin secretion.
Melatonin, produced by the pineal gland during darkness with peak levels between 2:00 and 4:00 AM, acts as a central modulator of circadian alignment and cardiovascular physiology.
Disruption of circadian rhythms – caused by factors such as artificial light at night, shift work, irregular sleep patterns, and mistimed feeding – leads to circadian misalignment.
This condition promotes autonomic imbalance characterized by increased sympathetic activity and reduced parasympathetic tone, alongside heightened oxidative stress and systemic inflammation.
These mechanisms contribute directly to endothelial dysfunction, impaired vascular reactivity, and loss of normal nocturnal blood pressure dipping.
Melatonin exerts cardioprotective effects through antioxidant, anti-inflammatory, and autonomic regulatory pathways.
It enhances nitric oxide bioavailability, reduces reactive oxygen species, improves heart rate variability, and lowers blood pressure.
Consequently, circadian disruption combined with reduced melatonin signaling is associated with increased risk of hypertension, atherosclerosis, and overall cardiovascular disease.”
Title: Circadian Rhythm Disruptions and Cardiovascular Disease Risk: The Special Role of Melatonin
Authors: Jarosław Nuszkiewicz, Wojciech Rzepka, Julia Markiel, Marta Porzych, Alina Woźniak, Karolina Szewczyk-Golec
Read the Full Article on Current Issues in Molecular Biology (CIMB)
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
-
Jun 25, 2026, 15:23Jonas Kingo: ISTH 2026 in Paris Brings the Global Hemostasis Community Together
-
Jun 25, 2026, 15:21Balancing Therapeutic Progress and Emergency Preparedness in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Jun 25, 2026, 15:06Ifeanyichukwu Ifechidere: What If One of the Biggest Myth Fact About APS is Hidden in its Name?
-
Jun 25, 2026, 15:05Gopal Patidar: Advancing Haemovigilance and Global Collaboration at ISBT 2026
-
Jun 25, 2026, 14:52Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety